Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres

Blanco, Mateo; Alonso, María José

doi:10.1016/s0939-6411(97)00056-8

Cited by 245 publications

(104 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Preparation of Targeted Nanoparticles PE38KDEL-I-loaded PLGA nanoparticles were prepared as described by Blanco and Alonso (18). Briefly, 150 AL of an aqueous solution of PE38KDEL-I containing 10% trehalose (Sigma) was emulsified in 1.5 mL ethyl acetate (Frutarom) containing 40 mg PLGA by sonication (Branson Sonicator 450).…”

Section: Methodsmentioning

confidence: 99%

Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments

Gao

Kou²,

Chen³

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments

Gao

Kou²,

Chen³

et al. 2008

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

show abstract

“…Due to their hydrosolubility the preparation method is generally based on the [(water-in-oil)-in water] solvent evaporation technique. 75,104,105 Entrapment efficiencies generally range from 10% to 90%, 75,104,106 and nanoparticle contents from 1% or less 99,107,108 to more than 15%. 106 Apart from formulation issues inherent to peptide chemical instability or chemical reaction between peptides and polymer degradation products, 109 the formulation of peptide-loaded nanoparticles is similar to conventional drugs.…”

Section: Drug Loadingmentioning

confidence: 99%

“…112 Each nanoparticle formulation of protein is unique and requires specific adaptation and evaluation. Improved protein stability was achieved by altering preparation processes, 113 by changing polymer/copolymer, 105,114 by changing or mixing solvents, 49,113 by adding protective additives 110,111 such as hydrophilic polymers (PEG 115,116 ), surfactants (poloxamer 188 104,117 ), pro-teins (serum albumin, 118 gelatin 105 ), cyclodextrins 118,119 to the inner aqueous phase. Such formulation optimizations permitted sustained release of active protein over several weeks in vitro.…”

Section: Drug Loadingmentioning

confidence: 99%

Drug transport to brain with targeted nanoparticles

2005

View full text Add to dashboard Cite

Summary: Nanoparticle drug carriers consist of solid biodegradable particles in size ranging from 10 to 1000 nm (50 -300 nm generally). They cannot freely diffuse through the bloodbrain barrier (BBB) and require receptor-mediated transport through brain capillary endothelium to deliver their content into the brain parenchyma. Polysorbate 80-coated polybutylcyanoacrylate nanoparticles can deliver drugs to the brain by a still debated mechanism. Despite interesting results these nanoparticles have limitations, discussed in this review, that may preclude, or at least limit, their potential clinical applications. Long-circulating nanoparticles made of methoxypoly(ethylene glycol)-polylactide or poly(lactide-co-glycolide) (mPEG-PLA/ PLGA) have a good safety profiles and provide drug-sustained release. The availability of functionalized PEG-PLA permits to prepare target-specific nanoparticles by conjugation of cell surface ligand. Using peptidomimetic antibodies to BBB transcytosis receptor, brain-targeted pegylated immunonanoparticles can now be synthesized that should make possible the delivery of entrapped actives into the brain parenchyma without inducing BBB permeability alteration. This review presents their general properties (structure, loading capacity, pharmacokinetics) and currently available methods for immunonanoparticle preparation.

show abstract

“…ionisation of chemical groups on the surface or adsorption of ions [28]. It has been previously reported [29,30] that the negative charge of PLGA nanoparticles is due to the ionisation of carboxylic-end groups of polymer on the surface. However, carboxylic end groups of the PLGA used in this study were esterified with lauryl groups and hence were not susceptible to ionisation.…”

Section: Characteristics Of Xan and 3-meoxan-loaded Nanospheresmentioning

confidence: 99%

Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone

Teixeira

Alonso

Pinto

et al. 2005

European Journal of Pharmaceutics and Biopharmaceutics

158

View full text Add to dashboard Cite

The aim of the present work was to develop and characterize two different nanosystems, nanospheres and nanocapsules, containing either xanthone (XAN) or 3-methoxyxanthone (3-MeOXAN), with the final goal of improving the delivery of these poorly water-soluble compounds. The xanthones-loaded nanospheres (nanomatrix systems) and nanocapsules (nanoreservoir systems), made of poly(DL-lactideco-glycolide) (PLGA), were prepared by the solvent displacement technique. The following characteristics of nanoparticle formulations were determined: particle size and morphology, zeta potential, incorporation efficiency, thermal behaviour, in vitro release profiles and physical stability at 4 8C. The nanospheres had a mean diameter !170 nm, a narrow size distribution (polydispersity index !0.1), and a negative surface charge (zeta potential !K36 mV). Their incorporation efficiencies were 33% for XAN and 42% for 3-MeOXAN. The presence of the xanthones did not affect the nanospheres size and zeta potential. DSC studies indicated that XAN and 3-MeOXAN were dispersed at a molecular level within the polymeric nanomatrix. Nanocapsules were also nanometric (mean size !300 nm) and exhibited a negative charge (zeta potential !K36 mV). Their incorporation efficiency values (O77%) were higher than those corresponding to nanospheres for both xanthones. The release of 3-MeOXAN from nanocapsules was similar to that observed for the correspondent nanoemulsion, indicating that drug release is mainly governed by its partition between the oil core and the external aqueous medium. In contrast, the release of XAN from nanocapsules was significantly slower than from the nanoemulsion, a behaviour that suggests an interaction of the drug with the polymer. Nanocapsule formulations exhibited good physical stability at 4 8C during a 4-month period for XAN and during a 3-month period for 3-MeOXAN. q

show abstract

Development and characterization of protein-loaded poly(lactide-co-glycolide) nanospheres

Cited by 245 publications

References 25 publications

Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments

Treatment of hepatocellular carcinoma in mice with PE38KDEL type I mutant-loaded poly(lactic-co-glycolic acid) nanoparticles conjugated with humanized SM5-1 F(ab′) fragments

Drug transport to brain with targeted nanoparticles

Development and characterization of PLGA nanospheres and nanocapsules containing xanthone and 3-methoxyxanthone

Contact Info

Product

Resources

About